Author summary Safety-related failures remain a substantial challenge in drug development, often emerging late in clinical trials or post-marketing. To address this, we developed a genomic-led framework that anticipates adverse drug reactions (ADRs) by levera…
Read Full ArticleThis article was originally published on Plos.org. Click the button above to read the complete article.
